Indian startup Lenskart fails to live up to its eye-popping valuation after going publciNovember 12, 2025
Share Facebook Twitter LinkedIn Pinterest Email Bill Sibold, Madrigal Pharma CEO, joins ‘Fast Money’ to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.